DS-MB-03521 recognizes the glycoprotein of rabies virus, a Lyssavirus that causes rabies in mammals. The virus is found in the saliva of infected animals and is mostly spread though bites. The virus then travels though the peripheral nervous system to the central nervous system. Once it reaches the brain it causes acute encephalitis. Symptoms include paralysis, cerebral dysfunction, anxiety, insomnia, confusion, anger, paranoia, terror and hallucination. The production of a large amount of saliva, the inability to speak or swallow and associated hydrophobia is also common in the later stages of the disease. The time between exposure to the virus and onset of symptoms can range from about 2 weeks to several months. Once symptoms appear, death is virtually inevitable. However, the disease can be effectively treated by post-exposure prophylaxis, through vaccination, provided this is done as soon as possible. DS-MB-03521 recognizes the purified glycoprotein of the rabies virus as well as the native virus. It has been shown to react with intact infected BHK cells and has therapeutic effect on infected mice. The antibody has virus-neutralizing activity with several rabies virus strains such as CVS, Lagos bat, Mokola, Flury LEP and Duvenhage.